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Bridging the Genetical Environmental Gap in 
Parkinson's Disease through Epigenetics
Abstract
Parkinson's Disease (PD) is a progressive neurodegenerative disorder affecting 2% 
of the population over 60 years old, yet the exact molecular mechanism underlying 
its pathogenesis remains elusive. PD is a multifactorial disease with genetic and 
environmental factors intricately associated.
Recently, epigenetic mechanisms have been recognized as potential mediators of 
environmental factors participating in the pathogenesis of PD. Epigenetics refer 
to the heritable changes in gene expression that do not involve changes to the 
underlying DNA sequence. Altered epigenetic mechanisms have been attributed 
to PD, Alzheimer’s and Huntington’s disease. Several studies have shown that DNA 
methylation, histone modifications and non-coding RNAs mechanisms contribute 
to the pathogenesis of PD. Accumulation of toxic metals such as manganese 
and iron, due to abnormal environmental exposure or increased dietary intake, 
can impact varied components of the epigenetic machinery through free radical 
formation.
Current pharmacological agents only provide symptomatic relief, of which 
levodopa still remains the gold standard. However, drugs that halt or delay 
progression of PD are still lacking. In recent years, there has been considerable 
progress in the development of epigenetic drugs as a novel therapeutic modality 
in the management of PD. Cell replacement therapy is a promising avenue for the 
treatment of PD with scientific research making great progress in the development 
of Induced Pluripotent Stem Cells (iPSCs) to produce midbrain dopamine 
phenotypes. With direct access to the neurons that are affected in PD, the pace of 
discovery should speed up and the cure for PD should become an attainable goal.
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Pathological Features
The histopathological trait of PD is the presence of fibrillar 
aggregates known as Lewy Bodies (LBs), with α-synuclein as 
the primary constituent. The presence of LBs may be seen as a 
representation of neuronal degeneration since neuronal loss is 
primarily found in the substantia nigra, locus coeruleus, nucleus 
basalis of Meynert, and the dorsal motor nucleus of the vagus, all 
of which are regarded as the predilection sites for LBs. Familial 
forms of PD are the consequence of mutations in the α-synuclein 
gene with α-synuclein protein being the major component of LBs 
in patients with sporadic PD [1].
It is also well known that there are numerous groups of 
dopaminergic neurons in the CNS, but not all deficits in dopamine 
accounts for PD. It is primarily the deficit of dopamine cells in 
the Substantia Nigra Pars Compacta (SNpc) that is thought to be 
responsible for all the motor complications of the disease. This 
selectivity goes further, in that not all of the dopamine neurons of 
the SNpc are involved with the disease. In fact, it is predominantly 
the ventral-lateral tier which is more severely affected compared 
to the dorsal tier. However, in the normal ageing process, it is 
the dorsal tier which is preferentially affected by a ratio of over 
3:1 compared to the ventral tier [2]. The pattern of cell loss seen 
in PD is unique as it neither occurs in other neurodegenerative 
diseases, nor in the normal ageing process. The reason behind 
such circumstantial susceptibility of cells affected in PD remains 
unclear.
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Etiological Factors
Over the past couple of years, human genetics has been in the 
forefront at providing multiple entry points in the understanding 
of the pathogenesis of PD. Whereas, mutations in α-synuclein 
and LRRK2 are predominantly regarded as dominant forms 
of inheritance, the recessive modes of inheritance in PD 
differ significantly to the sporadic disorder. The physiological 
function of α-synuclein is yet unknown but it is stipulated that 
loss of function may be associated with disease pathogenesis. 
Mutations in the parkin gene are distinct in that they result in 
an early onset clinical syndrome adopting a slow progression as 
opposed to the idiopathic disorder [3]. Recessive Parkinsonism is 
also seen in mutations in the DJ-1 protein which is implicated in 
the response to oxidative stress, however this provides minimal 
or no pathology whatsoever. Another autosomal recessive 
mutation is that seen with ATP13A2 (PARK9) gene which is 
associated with a juvenile-onset syndrome, adopting a levodopa-
responsive type of Parkinsonism called Kufor-Rakeb Syndrome 
(KRS). This involves a triad of pyramidal degeneration, cognitive 
impairment, and supranuclear palsy. Animal and cell culture 
studies taken from KRS patients suggest that PARK9 is important 
for both effective lysosomal and mitochondrial functioning, as 
well as for the clearance of divalent metals, wherein defects in 
any of these three processes would be intricately associated with 
neurodegeneration. Furthermore, recessive Parkinsonism may 
also be seen in mutations in PINK1, yet its pathological basis is 
yet to be characterized. However, there remain a considerable 
number of late-onset Parkinsonism patients bearing comparison 
to idiopathic PD with mutations in DJ-1, PINK1, and parkin, which 
supports their correlation to the sporadic disorder [4-6]. Research 
continues in an effort to shed additional light on the genetics of 
PD and to identify genes that contribute to its susceptibility.
Environmental risk factors for PD includes the exposure to heavy 
metals, pesticides and rural living, whilst cigarette smoking and 
caffeine are amongst two of the protective factors stipulated [2]. 
Accumulating evidence suggests that the exposure to pesticidal is 
associated with an increased risk for developing PD. Researchers 
have shown that there is a greater risk of developing PD in 
pesticide-exposed individuals with a gene variation affecting 
dopamine transport [7]. Heavy metals such as manganese, iron, 
copper, mercury, and lead are involved in neurologic disease. 
There is increasing recognition that heavy metals normally 
present in the body may also play a role in disease pathogenesis 
through free radical formation [8]. A collective study focusing 
on the effect of coffee consumption on Parkinson’s Disease (PD) 
concluded that consumption of coffee is more protective amongst 
individuals with a particular genotype compared to another 
genotype [9]. Furthermore, multiple studies have synergistically 
concluded that the incidence of PD in cigarette smokers is less 
than nonsmokers, with the number of years of smoking, being 
closely linked to lowering the risk of PD among smokers [10]. 
These discoveries have led to the suggestion that PD might 
arise due to the combined effects of ageing and environmental 
exposures that accelerate the process of nigral cell death.
There is a higher prevalence in PD associated with age-related 
attrition and death of dopaminergic neurons in the SNpc. Molecular 
and cellular changes of ageing cross-link with environmental 
and genetic factors in order to undermine which of the cells age 
successfully and which of them cease to neurodegeneration. It is 
unclear how this concept of selective vulnerability occurs, giving 
rise to different patterns of neurodegeneration in varying diseases 
[2]. Ageing bears correlation with oxidative stress, mitochondrial 
dysfunction, and greater free radical production leading to DNA 
mutations and genomic instability. This subsequently results in 
the shortening of telomeres which correlates to reduced survival 
[11]. Such age-related changes are relevant to the pathogenesis 
of PD, but the pattern and timing of such deficits is not the same 
in patients with PD, as there is no programming for neuronal 
death to arise at a specific time. Hence, despite being a risk factor 
for the disease, its mechanism in disease progression still remains 
elusive.
Such studies all show the incremental effect that the trident of 
ageing, genetics and environmental factors play to explain the 
pathogenesis of PD. Nonetheless, there still remains a missing 
part of the puzzle-that of which is the role of epigenetics which 
shall be the main focus of this review article.
Epigenetic Involvement in Parkinson’s 
disease
DNA methylation: DNA methylation is an epigenetic mechanism 
that cells use to control gene expression through the shifting of 
a methyl group (CH3) which occurs with the aid of DNA Methyl 
Transferases (DNMTs). A recent study conducted by Masliah 
et al., reported a decay on DNA methylation in the brains of 
PD patients, associated with the interaction of α-synuclein 
with DNMT1, which results in sequestration of DNMT1 in the 
cytoplasm [12]. In addition to α-synuclein, a number of additional 
genes have been studied to determine their significance in terms 
of DNA methylation in PD. A significant role in the pathogenesis of 
PD is thought to be due to neuroinflammation, with TNF-α being 
a critical inflammatory cytokine. Increased levels of TNF-α is 
associated with dopaminergic cell death in PD. A study conducted 
by Pieper and co-workers reported that hypomethylation of 
the TNF-α promoter in SNpc cells may explain the increased 
susceptibility of dopaminergic neurons to TNF-α mediated 
inflammatory reactions [13]. The list of implicated genes in DNA 
methylation is by no means solely restricted to α-synuclein and 
TNF-α, as a number of significant loci have been experimented by 
Plagnol et al. [14]. A large-scale sequencing analysis of postmortem 
brain samples identified DNA methylation alterations in PD risk 
variants in GPNMB/7p15, STX1B/16p11, and PARK16/1q32 loci. 
Such findings stipulate that additional PD related genes may be 
epigenetically modified in PD brains.
Currently, DNA methylation is being used as a successful biomarker 
in a number of cancers representing an extremely promising 
biomarker for neurodegenerative disorders [15]. As surfacing 
techniques nowadays allow for DNA methylation monitoring 
from easily accessible peripheral sites such as blood, an 
important question emerges, whether DNA methylation changes 
from Peripheral Blood Leukocytes (PBLs) would bear correlation 
with the brain methylome. Masliah and colleagues investigated 
genome-wide DNA methylation of brain and blood samples from 
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PD patients to that of control subjects, concluding that there is a 
substantial difference in methylation for many genes that were 
previously associated with PD pathology. Notably, this study 
showed harmonious alterations in DNA methylations in a subset 
of genes of brain and blood samples from PD patients, suggesting 
that PBLs might represent a good proxy for brain methylation 
alterations associated with PD [12]. This further reiterates the 
explanation of epigenetics as a molecular pathological mechanism 
in neurodegeneration and may also comprise an innovative entry 
point for biomarker discovery and development.
Histone Modifications
Histones play a key role in epigenetics, where conformational 
changes in either histone proteins or modifications in DNA 
wrapping may lead to gene silencing or activation. Histone 
acetylation with the aid of Histone Acetyl Transferases (HATs) 
is mainly associated with transcriptional activation machinery, 
whilst deacetylation catalysed by Histone Deacetylases (HDACs), 
correlates to transcriptional repression [16].
The most frequently studied histone modification is that of 
histone acetylation. Acetylation of histone tail leads to chromatin 
relaxation and transcriptional activation, whilst, deacetylation 
leads to condensation of the chromatin and transcriptional 
repression. Although, histone modifications have been well studied 
in many neurological disorders, little is still known concerning 
histone modifications in PD brains due to limited number of 
studies, with the majority of today’s knowledge obtained from 
cell studies and animal models, including mitochondrial toxins, 
such as rotenone, 1-methyl-4-phenylpyridinium (MPP+), and 
paraquat, or those over-expressing human α-synuclein. Studies 
have shown that α-synuclein inhibits histone acetylation thereby 
leading to neurotoxicity in both cell culture, as well as drosophila 
model of PD [17].
A number of studies have established a link between acetylation 
and neuroprotectivity, where Valproic acid has been implicated in 
the inhibition of histone deacetylase activity, and in an increase of 
histone H3 acetylation in brain tissues of rats with a subsequent 
neuroprotective effect in a rat model of PD [18]. This correlation 
was further solidified by Kidd and Schneider who reported that 
histone deacetylase inhibitors can protect dopaminergic neurons 
from MPP+ induced toxicity [19]. These varying studies indicate 
the potential of histone acetylation to be used as a beneficial 
clinical biomarker in the diagnosis of PD.
Another example of histone modification involves that of 
methylation, in which PINK1 is stipulated to be a major player. As 
previously described, mutations in PINK1 gene correlate to early 
onset recessive PD. It is stipulated to have a role in mitochondrial 
homeostasis but the exact mechanism by which it exerts its 
function remains elusive. A recent study which attempted to 
unveil its epigenetic molecular pathway stipulates that PINK1 
regulates histone H3 trimethylation and gene expression 
by interacting with the polycomb protein EED/WAIT1. This 
interaction favored the delocalization of the polycomb protein 
to the mitochondria, which in turn down regulated H3-K27 
trimethylation and altered gene transcription of differentiating 
SH-SY5Y human neuroblastoma cells [20].
Recent studies have also stipulated a role for PGC-1α in PD, 
which is involved in mitochondrial biogenetics and respiration. 
The activity of PGC-1α is under epigenetic control primarily 
through acetylation, as well as through methylation, sumoylation 
and protein phosphorylation. Transgenic mice showing 
overexpression of PGC-1α in dopaminergic neurons were found 
to be resistant to MPTP-induced cell degeneration, as well as 
showing elevated levels of the mitochondrial antioxidants Trx2 
and SOD2 in the substantia nigra. The drug resveratrol activated 
PGC-1α in dopaminergic cells via the deacetylase SIRT1, causing 
a reduction in PGC-1α acetylation, which in turn causes an 
increase in PGC-1α gene transcription with enhanced levels of 
the mitochondrial antioxidants. These results correlate with 
a neuroprotective effect from oxidative stress and cell death. 
An increase in PGC-1α has been associated with a reduction in 
dopaminergic neuron loss induced by α-synuclein mutations, 
whilst PGC-1α knockdown correlates with increased α-synuclein 
accumulation and an increased vulnerability to MPTP-induced 
dopaminergic degeneration in the substantia nigra. These 
findings offer a promising avenue for PGC-1α as a vital therapeutic 
target for neurodegenerative diseases; however, a greater 
understanding of the molecular pathways by which PGC-1α 
exert their neuroprotective effect is essential to develop optimal 
treatment for PD [21].
Non-Coding RNAs
MicroRNAs (miRNAs) are non-coding RNAs which suppress mRNA 
expression via translation inhibition, through binding to the 
3ʹ-Untranslated Region (3ʹUTR) of target RNAs.
In recent years, a number of studies using adult mice and 
embryonic stem cells differentiated into dopaminergic neurons, 
have emerged linking miRNAs to the pathogenesis of PD. 
MiRNAs are vital for the survival of dopaminergic neurons and 
their loss can be involved in the development and progression 
of PD. The first study which was conducted by Kim and co-
workers investigated the role of miRNAs in mammalian midbrain 
dopaminergic neurons and identified the absence of miR-133b 
in midbrain tissue from patients with PD, as opposed to control 
subjects. Subsequent studies further reinforced this finding, with 
several miRNAs found to play a key role in the pathogenesis of PD 
[22]. Decreased expression of miR-7 and miR-153 contributed to 
increased α-synuclein expression [23]. Furthermore, PD patients 
showed a decline in expression of hsc70 (targeted by miR-26b, 
miR-106a, miR-301b) and LAMP-2A (targeted by miR-21, miR-
224, miR-373) which are important proteins in the chaperone-
mediated autophagy responsible for the elimination α-synuclein 
in the SNpc. An increase in these miRNAs is the cause for the 
deregulation of proteins involved in clearing α-synuclein, thus 
leading to its aggregation which is involved in the pathogenesis 
of PD [24]. A recent study by Xiong et al. has demonstrated that 
upregulation of miR-494 predisposes to oxidative stress-induced 
neuronal death by inhibiting expression of DJ-1 [25]. Moreover, 
Cho and co-workers demonstrated that that downregulation of 
miR-205 may elevate LRRK2 protein in the brains of patients with 
sporadic PD, whereas over expression of the same miRNA may 
present a relevant therapeutic strategy to subdue the abnormal 
upregulation of LRRK2 protein in PD [26]. These results provide 
4
   This article is available in: http://www.clinical-epigenetics.imedpub.com/ 
2016
Vol. 2 No. 4: 22
Journal of Clinical Epigenetics
ISSN 2472-1158
an insight into the changes induced by miRNA expressions in the 
SNpc of PD subjects, which eventually regulate several important 
genes and pathways implicated in PD, which may subsequently 
provide a potential for the advancement of a range of miRNA-
based PD therapeutics.
The most recent discovery of non-coding RNAs has been that of 
the long non-coding RNAs (lncRNAs) in the SN of PD patients. 
Despite being minimally understood over the past few decades, 
the latest study conducted by Ni and colleagues sought to 
investigate the lncRNA expression profiles and their potential 
functions in patients with PD. LncRNA expression profiles in the 
SN of PD patients were screened, in which 87 lncRNAs were 
identified that were altered significantly in the SN during the 
occurrence of PD. Among these, the two lncRNAs that varied most 
dramatically were AK021630 and AL049437. AK021630 was down 
regulated while AL049437 was up regulated in the PD samples. 
According to the results obtained, the potential roles of these 
two lncRNAs were further investigated in the pathogenesis of PD 
by the knockdown of the expression of AL049437 or AK021630 
in human neuroblastoma SH-SY5Y cell line. The results showed 
that the knockdown of AK021630 level reduced cell viability, 
mitochondrial mass, mitochondrial trans membrane potential, 
and tyrosine hydroxylase (TyrH) secretion. On the other hand, 
the opposite effect was seen with reduction in AL049437. These 
findings suggest that the lncRNA AK021630 likely prevented the 
occurrence of PD whilst AL049437 likely contributed to the risk of 
developing PD [27].
Novel Therapeutic Approaches through 
Epigenetic Remodelling in PD
Despite a wide array of pharmacological drugs introduced since 
the discovery of levodopa, all current pharmacological agents 
available for managing PD solely provide symptomatic relief, 
since drugs that stop or retard PD progression are still lacking. 
Over the past few years, there has been a substantial progression 
in the development of epigenetic drugs for the treatment of 
neurodegenerative diseases, particularly the HDACs and DNMTs 
inhibitors.
DNMT inhibitors have been under a prolonged period of both 
preclinical and clinical investigations, with cytidine nucleoside 
analogs being the most widely studied of the DNMT inhibitors. 
They incorporate themselves into DNA following activation 
by a triphosphate moiety, with enzyme degradation taking 
place following the formation of an irreversible complex with 
DNMT1. This is responsible for the prevention of daughter DNA 
methylation in CpG islands during DNA replication [28].
The role of histone acetylation has been closely studied in multiple 
Parkinsonism models for its strong neuroprotective effects. 
Consequently, HDAC inhibitors are the latest derived therapeutic 
targets in treating PD. An important study conducted on both 
fly and cell models demonstrated that α-synuclein neurotoxicity 
may be protected by the administration of HDAC inhibitors. 
Alpha- synuclein has demonstrated to be capable of binding 
directly to histones, diminishing the amount of acetylated histone 
H3 in cultured cells [17]. The HDAC inhibitor VPA has shown 
to protect against rotenone, α-synuclein, lipopolysaccharide, 
and MPTP-mediated toxicity through the enhancement of H3 
histone acetylation, and reduction of inflammatory mediators in 
microglial cells. Independent of their actions on histones, HDAC 
inhibitors also contribute to modulating significant cytoprotective 
pathways, providing an additional beneficial effect to therapy. 
For instance, phenylbutyrate has been stipulated to protect DA 
neurons, potentially through increased DJ-1 expression and the 
activation of the tyrosine hydroxylase promoter in the SNpc [29].
Conjointly, these studies propose that HDAC inhibitors may be 
responsible for disease altering therapeutic benefits in various 
Parkinsonian model systems, and that they may also lead to 
the activation of additional pathways or genes that may render 
adjunctive neuroprotective effects. These pharmacological 
studies further reiterate the role of epigenetic regulation in the 
pathogenesis of PD.
Stem Cell Potential in PD
Stem cells are a promising source for cell replacement therapy due 
to their self-renewal and pluripotency ability which allows them 
to generate various cell types. Over the past few years, Induced 
Pluripotent Stem Cells (iPSCs) were developed as a promising cell 
source to generate disease-specific and personally-tailored cells 
[30]. Pluripotent stem cells have been used primarily as a cell 
model in order to understand the molecular mechanism of cellular 
differentiation, as well as a means for regenerative medicine. The 
latest discovery of iPS cells allowed the dissection of epigenetic 
regulation during differentiation and reprogramming [31].
Traditional in vitro and in vivo experimental models to study PD 
are suboptimal due to the lack of patient-specific nigral dopamine 
neurons for mechanistic studies and drug discovery [32]. Various 
human iPSCs from patients suffering different genetic forms of PD 
have been differentiated into dopamine neurons, rendering iPSCs 
a beneficial tool in studying the pathogenesis of PD [33].
The significance of epigenetic regulation in reprogramming 
and maintaining pluripotency is becoming more and more 
relevant. Current advancements in technology have got us 
to the stage where screening for genomic alterations at the 
entire genome level, has become a plausible possibility. It is 
of paramount importance to examine the epigenetic profile of 
iPSCs, since the epigenetic landscape is a representation of not 
only the past, but also the current developmental state, which 
may be a useful indicator to predict their potential in the future 
[31]. Novel reprogramming strategies which deter abnormal 
permanent genetic and epigenetic alterations are necessary to 
generate clinically-qualified iPSCs. Future investigations into cell 
reprogramming processes are needed to generate the disease-
specific iPSCs for personalised regeneration medicine of PD 
patients by disclosing detailed reprogramming mechanisms [34].
Concluding Remarks
We are now recognizing that epigenetic mechanisms are at the 
forefront in manipulating complex biological processes, yet we 
remain at the very surface in understanding the role which is 
played by such epigenetic variations in the pathophysiology of 
complex multifactorial diseases, as is the case with PD. We have 
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now benefitted from a better understanding of the pathways 
involved in dopaminergic neurodegeneration at a molecular 
level, thanks to the increasing number of published papers 
aimed at understanding the epigenetics of PD. In addition, 
many researchers are now working to gain understanding of the 
potential of pharmacological epigenetic drugs to counteract age-
related neurodegenerative diseases [26]. Research revealed that 
histone modifications, DNA methylation, and miRNA alterations 
often precede disease pathology, which might prove useful as 
early disease biomarkers. Additionally, they might be targeted 
with epigenetic drugs, such as, HDAC inhibitors, DNMT inhibitors, 
or drugs that target histone methyltransferases and histone 
demethylases, or SIRTs. The Human Epigenome Project has 
reached the stages of interpreting epigenetic profiles and their 
correlation to a number of varying pathologies. This epigenomic 
data should sequentially amalgamate both phenomic and 
genomic profiles in the context of both sporadic and familial 
PD, in order to generate a comprehensive understanding of the 
disease [35]. Future research should be aimed at understanding 
the cross-link between genetic components, environmental 
factors, and epigenetic biomarkers, in order to further identify 
individuals at risk of developing PD.
While pharmacological therapies have been shown to reduce 
symptoms of PD, they are by no means a form of cure. Cell 
replacement therapy is a promising avenue for the treatment 
of PD and other neurodegenerative disorders, with scientific 
research making great progress in the development of iPSCs for 
PD. With these new technologies, PD research is poised to enter a 
new phase, in which mechanistic studies, biomarker discoveries, 
and drug development will become more dependent on using 
iPSC-derived human midbrain DA neurons, both in vitro and 
in the brain of an animal model. These will open up unrivalled 
opportunities to change PD research significantly by redefining 
the disease in molecular and cellular terms, by predicting PD 
and tracking its progression, and by identifying new therapeutic 
strategies that can prevent or slow down the degeneration of 
nigral dopamine neurons [32]. Animal models using iPSCs have 
shown promise, but they are yet to be used in clinical trials for PD 
[33]. However, with rapid progress in iPSC-based technology, one 
can envision a bright future for PD research and it is therefore 
quite likely that within our lifetime we will witness the jump from 
dish to clinic.
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